1-2 of 2
Mark Goldberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

Clinical Trials & Observations
Adam Cuker, Alasdair J. Coles, Herman Sullivan, Edward Fox, Mark Goldberg, Pedro Oyuela, Annie Purvis, Diana S. Beardsley, David H. Margolin
Journal: Blood
Blood (2011) 118 (24): 6299–6305.
https://doi.org/10.1182/blood-2011-08-371138
Published: 2011
Includes: Supplemental data
Journal Articles

Incidence of Genomic Aberrations and Associated Efficacy from a Phase III Study Comparing Alemtuzumab (CAMPATH®, MABCAMPATH®) vs Chlorambucil as First Line Therapy for B-Cell Chronic Lymphocytic Leukemia (BCLL).

Tadeusz Robak, Anna Dmoszynska, Raouf Fetni, Ying Wang, Malika Belkacz, Cynthia Sirard, Mark Goldberg, Aleksander Skotnicki, Jiri Mayer, Peter Hillmen
Journal: Blood
Blood (2006) 108 (11): 2092.
https://doi.org/10.1182/blood.V108.11.2092.2092
Published: 2006